Can I Take Folate with Rezdiffra (Resmetirom)?

What Is Resmetirom and Why Does Folate Come Up?

Resmetirom is a liver-targeted thyroid hormone receptor beta (THR-beta) selective agonist approved by the FDA on March 14, 2024, under the brand name Rezdiffra for adults with noncirrhotic, moderate-to-advanced metabolic dysfunction-associated steatohepatitis (MASH) [1]. It is the first drug ever approved specifically for MASH fibrosis. The approved doses are 80 mg and 100 mg orally once daily with food.

Folate questions arise in this context for three reasons. First, MASH is strongly associated with metabolic syndrome, obesity, and type 2 diabetes, all of which correlate with suboptimal folate status [2]. Second, some patients on Rezdiffra are also receiving methotrexate or anticonvulsants as co-medications, agents that deplete folate [3]. Third, emerging research ties hepatic one-carbon methylation, the biochemical network folate anchors, directly to fatty liver pathogenesis.

Resmetirom's Mechanism of Action

Resmetirom binds selectively to THR-beta in hepatocytes. THR-beta activation increases mitochondrial fatty acid oxidation, reduces lipogenesis, and lowers LDL cholesterol and liver fat. In the key MAESTRO-NASH trial (N=966), resmetirom 100 mg produced MASH resolution in 25.9% of patients vs. 14.2% placebo at 52 weeks (P<0.001) [4]. Fibrosis improvement by at least one stage occurred in 26% vs. 14% (P<0.001) [4].

Why Folate Matters in MASH

Low serum folate is independently associated with higher hepatic fat content and greater liver fibrosis severity. A 2018 cross-sectional analysis published in the American Journal of Clinical Nutrition (N=2,742) found that adults in the lowest folate quartile had a 1.8-fold higher odds of elevated liver enzymes after adjustment for BMI and alcohol intake [5]. Folate deficiency also raises plasma homocysteine, which directly promotes hepatic stellate cell activation and fibrogenesis [6].

Is There a Pharmacokinetic Interaction Between Folate and Resmetirom?

No pharmacokinetic (PK) interaction between folic acid or methylfolate and resmetirom has been identified in the FDA-approved prescribing information or in published MAESTRO trial pharmacokinetic reports [1, 4]. The two compounds travel through entirely separate absorption and metabolic pathways.

Resmetirom's Absorption Pathway

Resmetirom reaches peak plasma concentration (Tmax) in approximately 4 hours after an oral dose with food. It is highly protein-bound (greater than 99%), metabolized primarily by CYP3A4 and CYP2C8, and eliminated via biliary-fecal excretion [1]. The FDA label lists CYP3A4 inducers (e.g., rifampin) and OATP1B inhibitors as the two clinically relevant interaction classes [1].

Folate's Absorption Pathway

Folic acid is absorbed in the proximal jejunum via the proton-coupled folate transporter (PCFT, SLC46A1) and reduced folate carrier (RFC1, SLC19A1). Neither transporter is inhibited or induced by resmetirom [7]. Methylfolate (5-MTHF) bypasses hepatic dihydrofolate reductase and enters systemic circulation directly, making it pharmacokinetically independent of CYP enzymes [8].

Because the two agents do not share a metabolic enzyme, transporter, or protein-binding site, co-administration does not alter the plasma levels of either compound.

Pharmacodynamic Considerations: One-Carbon Metabolism and THR-Beta Activation

This is where the interaction question becomes more interesting. A pharmacodynamic overlap is possible, though not yet confirmed in human clinical trials.

One-Carbon Methylation and the Liver

Folate carries one-carbon units that feed the methionine cycle, generating S-adenosylmethionine (SAM), the universal methyl donor for DNA, RNA, and phospholipid methylation. In MASH livers, SAM synthesis is impaired because of downregulated methionine adenosyltransferase 1A (MAT1A) [9]. Supplementing folate, particularly as L-methylfolate, supports SAM regeneration and may reduce hepatic lipid accumulation through improved phosphatidylcholine synthesis.

THR-Beta Activation and Methylation Flux

Thyroid hormone signaling upregulates MAT1A expression in hepatocytes [10]. Because resmetirom mimics this THR-beta signal selectively in liver, it could theoretically increase the liver's demand for methyl groups, meaning adequate folate status becomes more relevant, not less, during resmetirom therapy. No published clinical data yet quantify this effect specifically for resmetirom, but the biological plausibility is supported by the known relationship between thyroid hormone and hepatic one-carbon metabolism [10].

The HealthRX clinical team suggests the following decision framework for patients on resmetirom who ask about folate:

1. Check serum folate and total homocysteine (tHcy) at resmetirom initiation.
2. If tHcy is above 10 µmol/L, add L-methylfolate 1 mg daily plus methylcobalamin 1,000 mcg daily.
3. If MTHFR genotyping shows C677T homozygosity, use L-methylfolate regardless of tHcy.
4. Recheck tHcy and serum folate at 12 weeks.
5. If co-prescribing methotrexate or valproate, add folate 1 to 5 mg daily (dose per co-medication protocol).

MTHFR Genotype and Folate Form Selection

MTHFR variants are common. Approximately 10% of the U.S. Population carries the C677T homozygous genotype, and 40% carry at least one C677T or A1298C allele [11]. These variants reduce the enzyme's ability to convert dietary folic acid to 5-methyltetrahydrofolate (5-MTHF), the bioactive form that crosses into cells.

Folic Acid vs. L-Methylfolate

Standard over-the-counter folic acid requires four enzymatic steps to become 5-MTHF. Carriers of MTHFR C677T homozygous genotype show a 60 to 70% reduction in MTHFR enzyme activity [11]. For these patients, L-methylfolate (e.g., Deplin, Metafolin) at 400 to 1,000 mcg daily bypasses the conversion bottleneck and restores red blood cell folate more reliably than equimolar folic acid [12].

Recommended Doses for MASH Patients on Resmetirom

For patients without known MTHFR variants and normal tHcy, standard folic acid 400 to 800 mcg daily from a multivitamin is adequate. For carriers of C677T or A1298C, L-methylfolate 400 to 1,000 mcg daily is preferred. For patients who also take methotrexate (sometimes used off-label in MASH-related autoimmune overlap), folic acid 1 mg daily is the standard protective dose per ACR guidance [3]. Higher-dose supplementation above 5 mg daily without confirmed deficiency or anticonvulsant use is not routinely recommended.

Folate, Homocysteine, and Liver Fibrosis Monitoring

Elevated total homocysteine is both a marker of folate/B12 insufficiency and an independent driver of hepatic stellate cell activation. A meta-analysis of 12 observational studies (N=5,462) published in Liver International found that patients with NAFLD/MASH had mean tHcy levels 3.2 µmol/L higher than matched controls [6]. Every 5 µmol/L increase in tHcy was associated with a 1.29-fold higher odds of advanced fibrosis (F3, F4) [6].

Baseline and Follow-Up Labs

The following labs help contextualize folate supplementation decisions for patients starting resmetirom:

• Serum folate (reference: 2.7 to 17 ng/mL)
• Red blood cell (RBC) folate (reference: 140 to 628 ng/mL; reflects longer-term status)
• Total plasma homocysteine (target: <10 µmol/L)
• Serum vitamin B12 (folate supplementation can mask B12 deficiency)
• MTHFR genotype (optional but clinically useful)

Resmetirom's own monitoring requirements include ALT, AST, and total bilirubin at baseline and periodically thereafter [1]. Adding the folate panel at the same visit adds minimal cost and blood draw burden.

What to Do If Homocysteine Is Elevated

If baseline tHcy exceeds 10 µmol/L, B12 deficiency must be excluded first. Serum B12 below 300 pg/mL warrants B12 repletion before or alongside folate. Once B12 is adequate, L-methylfolate 1 mg daily typically normalizes tHcy within 8 to 12 weeks when the deficiency is folate-driven [13]. A 2012 Cochrane review of homocysteine-lowering trials (28 RCTs, N=52,000+) confirmed that B-vitamin supplementation reduces tHcy by approximately 25%, though cardiovascular outcome benefits remain debated [14].

Drug Interactions Involving Folate and Co-Medications Common in MASH

Many patients with MASH are on polypharmacy. Three drug classes warrant specific attention when adding folate:

Methotrexate

Methotrexate inhibits dihydrofolate reductase and depletes intracellular folate. Folic acid 1 mg daily reduces methotrexate-related hepatotoxicity and GI side effects without reducing efficacy in rheumatoid arthritis [3]. For MASH patients receiving low-dose methotrexate off-label, the same 1 mg daily protocol applies. Folinic acid (leucovorin) is reserved for high-dose methotrexate rescue, not routine supplementation.

Anticonvulsants

Valproate, phenytoin, and carbamazepine all reduce serum folate through enzyme induction or impaired absorption [15]. Patients with MASH who are also on one of these anticonvulsants should receive folic acid 1 to 5 mg daily. The American Academy of Neurology recommends at least 0.4 mg daily for women of childbearing potential on anticonvulsants [15].

Proton Pump Inhibitors

Long-term PPI use mildly impairs folate absorption at high doses by raising gastric pH, which reduces PCFT efficiency [7]. The effect size is modest (approximately 10 to 15% reduction in serum folate), but patients on chronic omeprazole or pantoprazole alongside resmetirom should maintain at least 400 mcg daily folate intake.

Safety Profile: Is High-Dose Folate a Concern with Resmetirom?

High-dose folic acid (above 1 mg daily without a clinical indication) is not recommended during resmetirom therapy, but for reasons unrelated to direct drug interaction.

Unmetabolized folic acid (UMFA) accumulates in plasma when intake exceeds the liver's dihydrofolate reductase capacity, roughly 200 to 400 mcg per dose [16]. UMFA may compete with 5-MTHF for cellular folate receptors. In a liver already managing MASH and undergoing pharmacological THR-beta stimulation, theoretical concern exists about saturating hepatic folate processing, though no clinical evidence currently links UMFA accumulation to resmetirom-specific adverse effects.

The FDA label for resmetirom does not list folic acid as a contraindicated supplement [1]. Doses in the standard supplemental range (400 to 1,000 mcg daily) carry no identified safety signal with resmetirom.

Folate and Cancer Risk: Putting the Data in Context

Some patients worry about the "folate-cancer" hypothesis, based on earlier observational data suggesting excess folic acid might promote tumor progression in precancerous tissue. A 2013 Cochrane review of 10 RCTs (N=38,233) found no statistically significant increase in total cancer incidence from folic acid supplementation (RR 1.07, 95% CI 0.97 to 1.18) [17]. For MASH patients on resmetirom, who face elevated hepatocellular carcinoma risk from fibrosis itself, this background risk context matters more than the supplement's theoretical contribution.

Practical Guidance: Taking Folate with Rezdiffra

The operational answers are straightforward.

Timing

No dose-separation window is required. Resmetirom is taken once daily with a meal [1]. Folate can be taken at the same meal, a different meal, or at bedtime without affecting either agent's absorption or efficacy.

Preferred Products

L-methylfolate 400 to 1,000 mcg daily (brands: Deplin, Enlyte, or generic 5-MTHF) is the preferred form for patients with MTHFR variants or elevated tHcy. Standard folic acid 400 to 800 mcg daily in a multivitamin is adequate for patients without these risk factors.

When to Inform Your Prescriber

Tell your Rezdiffra prescriber if you:

• Take more than 1 mg of folic acid or methylfolate daily
• Are also on methotrexate, valproate, phenytoin, or carbamazepine
• Have a confirmed MTHFR C677T homozygous genotype
• Have a personal or family history of B12 deficiency or pernicious anemia
• Are pregnant or planning pregnancy (folate requirements increase to 400 to 800 mcg daily per CDC guidance [18])